A 52-weeks Observational Study to Evaluate the Safety of Brolucizumab in Patients With nAMD

The observational period was 1 year (52 weeks) from the first brolucizumab administration in the primary treated eye. However, if brolucizumab was discontinued in the primary treated eye and if the treatment was discontinued less than 52 weeks observation period, the observation period was to be up to 90 days after the last dose of this drug. This was set in order to collect data as much as possible based on the clinical effect of the drug. If 30 days after the last dose of this drug in a discontinued patient exceeds 52 weeks of the observation period, the patient was to be monitored for adverse events until 30 days after the last dose of this drug.